13
Aug
2019

Landmark chlamydia vaccine passes first stage of human trials

“We took blood samples of the women during the trial,” explains Frank Follmann, from Statens Serum Institut (SSI) in Denmark and co-author on the new research. “They showed that all vaccinated women had generated specific antibodies and T cells against chlamydia. Also, as local immunity in the genital tract is important to stop the infection as quickly as possible, during the trial, we collected mucous secretion in a menstrual cup and found high levels of antibodies, including the special mucosal antibody, IgA, which effectively blocks chlamydia early in the course of infection.”

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.